Biomarker evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus cetuximab (Cet) in ≥2 line recurrent/metastatic (R/M) squamous cell carcinomas of the head and neck (SCCHN) [MEHGAN]

被引：0
|
作者：
Pennel, Elicia [1 ]
Kapp, Amy V. [1 ]
Do, An [1 ]
Tam, Rachel [1 ]
Sumiyoshi, Teiko [1 ]
Marathe, Chaitra [1 ]
Sa, Susan [1 ]
Peale, Franklin [1 ]
Lackner, Mark [1 ]
Holden, Scott [1 ]
Seiwert, Tanguy [2 ]
Pirzkall, Andrea [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Chicago, Chicago, IL 60637 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1553
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1553
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).
    Fury, M. G.
    Sherman, E. J.
    Lisa, D. M.
    Agarwal, N.
    Algazy, K. M.
    Brockstein, B.
    Langer, C. J.
    Lim, D.
    Mehra, R.
    Rajan, S. K.
    Jafri, N.
    Korte, S.
    Lipson, B.
    Yunus, F.
    Tanvetyanon, T.
    Smith-Marrone, S.
    Ng, K. K.
    Xiao, H.
    Haque, S.
    Pfister, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Cetuximab 1 platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE)
    Le Tourneau, C.
    Ghiani, M.
    Cau, M. C.
    Depenni, R.
    Ronzino, G.
    Bonomo, P.
    Montesarchio, V.
    Leo, L.
    Schulten, J.
    Messinger, D.
    Sbrana, A.
    Ghi, M. G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover
    Cupissol, Didier
    Seiwert, Tanguy Y.
    Fayette, Jerome
    Ehrnrooth, Eva
    Blackman, Alice Sarah
    Cong, Xiuyu Julie
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study.
    Saba, Nabil F.
    Kono, Scott A.
    Mendel, Jennifer Robin
    Hurwitz, Selwyn J.
    Owonikoko, Taofeek Kunle
    Lewis, Colleen Margaret
    Harvey, Donald
    Rogerio, Jaqueline Willemann
    Chen, Zhengjia
    Wadsworth, Trad
    El-Deiry, Mark
    Chen, Amy Y.
    Higgins, Kristin
    Ramalingam, Suresh S.
    Beitler, Jonathan Jay
    Shin, Dong M.
    Khuri, Fadlo Raja
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Albiruni R. Abdul Razak
    Hung-Ming Wang
    Jang-Yang Chang
    Myung-Ju Ahn
    Pamela Munster
    George Blumenschein
    Benjamin Solomon
    Darren Wan-Teck Lim
    Ruey-Long Hong
    David Pfister
    Nabil F. Saba
    Se-Hoon Lee
    Carla van Herpen
    Cornelia Quadt
    Douglas Bootle
    Lars Blumenstein
    David Demanse
    Jean-Pierre Delord
    Targeted Oncology, 2023, 18 : 853 - 868
  • [46] A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Razak, Albiruni R. Abdul
    Wang, Hung-Ming
    Chang, Jang-Yang
    Ahn, Myung-Ju
    Munster, Pamela
    Blumenschein Jr, George
    Solomon, Benjamin
    Lim, Darren Wan-Teck
    Hong, Ruey-Long
    Pfister, David
    Saba, Nabil F.
    Lee, Se-Hoon
    van Herpen, Carla
    Quadt, Cornelia
    Bootle, Douglas
    Blumenstein, Lars
    Demanse, David
    Delord, Jean-Pierre
    TARGETED ONCOLOGY, 2023, 18 (06) : 853 - 868
  • [47] CETUXIMAB RELATIVE DOSE INTENSITY (RDI) IN RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): FIRST OBSERVATIONAL PROSPECTIVE STUDY IN UNSELECTED PATIENTS (DIRECT TRIAL)
    Guigay, J.
    Peyrade, F.
    Petre-Lazar, B.
    Mornex, F.
    Ceruse, P.
    Digue, L.
    Berrier, A.
    Degardin, M.
    Alfonsi, M.
    Artignan, X.
    Cals, L.
    Faivre, S.
    Vuillemin, E.
    Rolland, F.
    Timochenko, A.
    Babin, E.
    Prevost, A.
    Romano, O.
    Chamorey, E.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2014, 25
  • [48] Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCiD).
    Knoedler, Maren
    Dietz, Andreas
    Gauler, Thomas Christoph
    Gruenwald, Viktor
    Stoehlmacher, Jan
    Knipping, Stephan
    Guntinas-Lichius, Orlando
    Frickhofen, Norbert
    Schroeder, Michael
    Maschmeyer, Georg
    Rethwisch, Volker
    Haxel, Boris
    Keilholz, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Cetuximab, Fluorouracil (5-FU), Ciplatin and Docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCID).
    Knoedler, M.
    Dietz, A.
    Gauler, T.
    Stoehlmacher-Williams, J.
    Gruenwald, V
    Rethwisch, V.
    Frickhofen, N.
    Haxel, B.
    Schroeder, M.
    Knipping, S.
    Maschmeyer, G.
    Guntinas-Lichius, O.
    Keilholz, U.
    ONKOLOGIE, 2013, 36 : 94 - 94
  • [50] An analysis of toxicity in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving cetuximab, fluorouracil and cisplatin alone or with docetaxel in a phase II clinical trial (CeFCiD)
    Knoedler, M.
    Dietz, A.
    Gauler, T.
    Stoehlmacher, J.
    Gruenwald, V
    Rethwisch, V
    Frickhofen, N.
    Haxel, B.
    Schroeder, M.
    Knipping, S.
    Maschmeyer, G.
    Guntinas-Lichius, O.
    Keilholz, U.
    ONKOLOGIE, 2012, 35 : 153 - 153
12345